Table 1 Summary of data collected from each of the four studies
From: Exploration of refined humane endpoints for melioidosis in BALB/c mice
Parameter | Study 111 | Study 2a | Study 312 | Study 413 |
|---|---|---|---|---|
Number of mice | 105 | 110 | 135 | 206 |
Number (%) reaching predefined end of study | 67 (63.8%) | 92 (83.6%) | 116 (85.9%) | 123 (59.7%) |
Number (%) reaching humane endpoint | 34 (32.4%) | 16 (14.5%) | 19 (14.1%) | 76 (36.9%) |
Number (%) succumbing to infection before being euthanized | 4 (3.8%) | 2 (1.8%) | 0 (0%) | 7 (3.4%) |
Study duration (post-challenge in days) | 66 | 53 | 43 | 36 |
Number of treatment comparison groups | 3 | 2 | 4 | 3 |
Challenge dose (mean retained dose in CFU) | 142 | 62 | 100 | 106 |
Treatment duration (days) | 14 | 14, 14b | 14 | 7 |
Treatment start time (h) | 24 | 24 | 24 or 36 | 36 or 48 |
